Table 3.

Pooled HRs for DFS and subgroup analysis of TIM-3 expression in solid cancer patients.

Categories	Number of studies	Number of patients	Random effects model		Heterogeneity		P-value
			Pooled HR	95% CI	I2	PH value
DFS	7	1243	1.39	0.75–2.57	86.9%	<0.001	0.297
EXPRESSION LOCATION
Tumor cells	2	239	2.10	0.99–4.46	0.0%	0.925	0.053
TILs	5	920	1.06	0.42–2.65	92.1%	<0.001	0.904
Tumor cell+TILs	1	223	2.32	1.44–3.73	-	-	0.001
TUMOR TYPE
ESCC	2	579	2.42	0.94–6.26	90.4%	0.001	0.068
NSCLC	2	362	2.40	1.69–3.41	0.0%	0.876	<0.001
Others	3	302	0.40	0.11–1.46	73.9%	0.022	0.164
SAMPLE SIZE
<100	1	93	0.43	0.22–0.82	-	-	0.010
≥100	6	1,150	1.71	0.97–3.04	82.4%	<0.001	0.066
METHOD TO ESTIMATE HR
Multivariate	5	1,004	1.05	0.45–2.44	92.1%	<0.001	0.916
Univariate	2	239	2.45	1.48–4.05	0.0%	0.864	<0.001

DFS, disease-free survival; TIL, tumor infiltrating lymphocyte, ESCC, esophageal squamous cell carcinoma; NSCLC: Non-small cell lung cancer.